Goel S, Marwah A, Kaushik S, Garg VK, Gupta S. Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus. J Clin Exp Dent. 2015;7(4):e477-82.

 

doi:10.4317/jced.52376

http://dx.doi.org/doi:10.4317/jced.52376

 

References

1. Carrozzo M, Uboldi de Capei M, Dametto E, Fasano ME, Arduino P, Broccoletti R, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol. 2004;122:87-94. Erratum in: J Invest Dermatol. 2004;123:805.
http://dx.doi.org/10.1046/j.0022-202X.2003.22108.x
PMid:14962095

 

2. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in Oral lichen planus: report of an international concensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:164-78.
http://dx.doi.org/10.1016/j.tripleo.2004.06.076
PMid:16037774

 

3. Ishii T. Immunohistochemical demonstration of T cell subsets and accessory cells in Oral lichen planus. J Oral Pathol Med. 1987;16:356-61.
http://dx.doi.org/10.1111/j.1600-0714.1987.tb00708.x

PMid:3117990

 

4. Gu GM, Martin MD, Darveau RP, Truelove E, Epstien J. Oral and Serum IL-6 levels in oral lichen planus patients. Oral Surg Oral Med Oral Pathol Radiol Endod. 2004;98:673-8.
http://dx.doi.org/10.1016/j.tripleo.2004.05.006

PMid:15583539

 

5. Zhang Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, et al. NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine. 2008;41:144-9.
http://dx.doi.org/10.1016/j.cyto.2007.11.004
PMid:18222093

 

6. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med. 2002;31:196-203.
http://dx.doi.org/10.1034/j.1600-0714.2002.310402.x
PMid:12076322

 

7. Nibali L, Fedele S, D'Aiuto F, Donos N. Interleukin-6 in oral diseases: a review. Oral Dis. 2012;18:236-43.
http://dx.doi.org/10.1111/j.1601-0825.2011.01867.x
PMid:22050374

 

8. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther. 2010;87:483-7.
http://dx.doi.org/10.1038/clpt.2009.313
PMid:20182422

 

9. Dreuw A, Hermanns HM, Heise R, Joussen S, Rodríguez F, Marquardt Y, et al. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J Invest Dermatol. 2005;124:28-37.
http://dx.doi.org/10.1111/j.0022-202X.2004.23499.x
PMid:15654950

 

10. Gasche C, Reinisch W, Huber WD, Leshinsky-Silver E, Levine A, Abdul-Baki H, et al. IL-10RA truncation mutations and Semite populations. Inflamm Bowel Dis. 2011;17:1438.
http://dx.doi.org/10.1002/ibd.21495
PMid:20842643

 

11. Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1991;72:665-70.
http://dx.doi.org/10.1016/0030-4220(91)90007-Y

PMid:1812447

 

12. Ibrahim SS, Hazzaa HH. Topical pimecrolimus effect on Fas inducing apoptosis in oral lichen planus, a clinical immunohistochemical study. J oral pathol Med. 2012;41:315-21.
http://dx.doi.org/10.1111/j.1600-0714.2011.01099.x
PMid:22085391

 

13. Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC. William WH. Effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontol. 2005;76:627-35.
http://dx.doi.org/10.1902/jop.2005.76.4.627
PMid:15857105

 

14. Gorouhi F, Solhpour A, Beitollahi JM, Afshar S, Davari P, Hashemi P, et al. Randomised trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of lichen planus. J Am Acad Dermatol. 2007;57:806-13.
http://dx.doi.org/10.1016/j.jaad.2007.06.022
PMid:17658663

 

15. Allen BR1, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child. 2003;88:969-73.
http://dx.doi.org/10.1136/adc.88.11.969
PMCid:PMC1719352

 

16. Volz T, Caroli U, Lüdtke H, Bräutigam M, Kohler-Späth H, Röcken M, et al. Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. Br J Dermatol. 2008;159:994.
http://dx.doi.org/10.1111/j.1365-2133.2008.08726.x
PMid:18647310

 

17. McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM. Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. J Eur Acad Dermatol Venereol. 2011;25:1061-7.
http://dx.doi.org/10.1111/j.1468-3083.2010.03923.x
PMid:21175873

 

18. Frieling U, Bonsmann G, Schwarz T, Luger TA, Beissert S. Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol. 2003;49:1063-6.
http://dx.doi.org/10.1016/S0190-9622(03)02111-X

PMid:14639385

 

19. Nylander Lundqvist E, Wahlin YB, Hofer PA. Methotrexate supplemented with steroid ointments for the treatment of severe erosive lichen ruber. Acta Derm Venereol. 2001;82:63-4.
http://dx.doi.org/10.1080/000155502753600966

PMid:12013206

 

20. Torti DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol. 2007;143:511-5.
http://dx.doi.org/10.1001/archderm.143.4.511
PMid:17438185

 

21. Kanwar AJ, De D. Methotrexate for treatment of lichen planus: old drug, new indication. J Eur Acad Dermatol Venereol. 2013;27:410-3.
http://dx.doi.org/10.1111/j.1468-3083.2012.04654.x
PMid:22827806

 

22. Dalmau J, Puig L, Roé E, Peramiquel L, Campos M, Alomar A. Successful treatment of oral erosive lichen planus with mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2007;21:259-60.
PMid:17243970

 

23. Wee J S, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients. Br J Dermatol. 2012;167:36-43.
http://dx.doi.org/10.1111/j.1365-2133.2012.10882.x
PMid:22309851

 

24. Yamamoto T, Yoneda K, Ueta E, Hirota J, Osaki T. Serum cytokine levels in patients with oral mucous membrane disorders. J Oral Pathol Med. 1991;20:275-9.
http://dx.doi.org/10.1111/j.1600-0714.1991.tb00927.x
PMid:1890662

 

25. Karagouni EE, Dotsika EN, Sklavounou A. Alteration in peripheral blood mononuclear cell function and serum cytokines in oral lichen planus. J Oral Pathol Med. 1994;23:28-35.
http://dx.doi.org/10.1111/j.1600-0714.1994.tb00250.x
PMid:8138978

 

26. Fayyazi A, Schweyer S, Soruri A, Duong LQ, Radzun HJ, Peters J, et al. T lymphocytes and altered keratinocytes express interferon-gamma and interleukin 6 in lichen planus. Arch Dermatol Res. 1999;291:485-90.
http://dx.doi.org/10.1007/s004030050442
PMid:10541878

 

27. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904-10.
http://dx.doi.org/10.1016/j.ctrv.2012.04.007
PMid:22651903

 

28. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125-39.
http://dx.doi.org/10.1016/j.pharmthera.2013.09.004
PMid:24076269

 

29. Nagy SE, Andersson JP, Andersson UG. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines. Immunopharmacology. 1993;26:11–20.
http://dx.doi.org/10.1016/0162-3109(93)90062-U

PMid:8407281